With this year’s iteration of the J.P. Morgan Healthcare Conference in the rearview mirror, the biopharma industry has officially closed the door on 2025 as it heads into what is sure to be another eventful year.

In this week’s episode of "The Top Line," Fierce Pharma's Zoey Becker sits down with Angus Liu and Fierce Biotech's Gabrielle Masson to unpack the key topics and trends that stood out at this year's conference in San Francisco. The conversation offers an early look at the themes and questions that could shape the year ahead.

To learn more about the topics in this episode: 


All the meetings, none of the megadeals: Is JPM's purpose evolving?


JPM26: What’s in a biopharma? CEO says Teva has the goods


JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears 

With this year&rsquo;s iteration of the J.P. Morgan Healthcare Conference in the rearview mirror, the biopharma industry has officially closed the door on 2025 as it heads into what is sure to be another eventful year.
In this week&rsquo;s episode of "The Top Line," Fierce Pharma's Zoey Becker sits down with Angus Liu and Fierce Biotech's Gabrielle Masson to unpack the key topics and trends that stood out at this year's conference in San Francisco. The conversation offers an early look at the themes and questions that could shape the year ahead.
To learn more about the topics in this episode:&nbsp;
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/all-meetings-none-mega-deals-jpms-purpose-evolving">All the meetings, none of the megadeals: Is JPM's purpose evolving?</a>
</li>
<li>
<a href="https://www.fiercepharma.com/pharma/jpm-2026-biosimilars-biopharma-teva-walks-walk-2026">JPM26: What&rsquo;s in a biopharma? CEO says Teva has the goods</a>
</li>
<li>
<a href="https://www.fiercepharma.com/pharma/astellas-ceo-resists-rescue-bd-6b-xtandi-patent-cliff-nears">JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears</a>&nbsp;
</li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;